Use of F-18 Fluorodeoxyglucose Positron Emission Tomography with Dual-Phase Imaging to Identify Intraductal Papillary Mucinous Neoplasm.

Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan. Electronic address: .
Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association (Impact Factor: 5.64). 11/2012; DOI: 10.1016/j.cgh.2012.10.037
Source: PubMed

ABSTRACT BACKGROUND & AIMS: We investigated the usefulness of dual-phase, F-18 fluorodeoxyglucose positron emission tomography with computed tomography (FDGPET/CT) to differentiate benign from malignant intraductal papillary mucinous neoplasms (IPMNs) and evaluate branch-duct IPMNs. METHODS: We used FDG-PET/CT to evaluate IPMNs in 48 consecutive patients, from May 2004 to March 2012, who underwent surgical resection. IPMNs were classified as benign (n=16) or malignant (n=32) based on histology analysis. The ability of FDG-PET/CT to identify branch-duct IPMNs was compared with that of the International Consensus Guidelines. RESULTS: The maximum standardized uptake value (SUV(max)) was higher for early-phase malignant IPMNs than that for benign IPMNs (3.5±2.2 vs 1.5±0.4;P <.001). When the SUV(max) cut-off value was set at 2.0, early-phase malignant IPMNs were identified with 88% sensitivity, specificity, and accuracy. The retention index (RI) values for malignant and benign IPMNs were 19.6±17.8 and -2.6±12.9, respectively. When the SUV(max) cut-off was set to 2.0 and the RI value to -10.0, early-phase malignant IPMNs were identified with 88% sensitivity, 94% specificity, and 90%, accuracy. In identification of branch-duct IPMNs, when the SUV(max) cut-off was set to 2.0, the sensitivity, specificity, and accuracy values were 79%, 92%, and 84%, respectively. Using a maximum main pancreatic duct diameter =7 mm, the Guidelines identified branch-duct IPMNs with greater specificity than FDG-PET/CT. The Guideline criteria of maximum cyst size =30 mm and the presence of intramural nodules identified branch-duct IPMNs with almost equal sensitivity to FDGPET/CT. CONCLUSIONS: Dual-phase FDG-PET/CT is useful for preoperative identification of malignant IPMN and for evaluating branch-duct IPMN.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of our study is to establish the potential role of dual-phase 18F-fluorodeoxyglucose positron emission tomography / computed tomography (FDG-PET/CT) in patients presenting ovarian masses with diffuse peritoneal infiltration for differentiating benign from malignant lesions. Twenty patients (13 with ovarian cancers and 7 with benign lesions) were evaluated preoperatively by dual-phase 18F-FDG-PET/CT performed 1 h and 2 h after injection of 18F-FDG. The maximum standardized uptake value (SUVmax) for both time points SUVmax1 and SUVmax2 were determined, respectively, and the retention index (RI) was calculated by subtracting the SUVmax1 from the SUVmax2 and dividing by SUVmax1. The areas under the receiver operating characteristic curves (AUCs) of SUVmax1 and SUVmax2 were 0.753 (P = 0.062, 95 % confidence interval [CI] = 0.512-0.915) and 0.835 (P = 0.001, 95 % CI = 0.604-0.961), respectively. The AUC of the RI was 0.901 (P < 0.001, 95 % CI = 0.684-0.988). Using pairwise comparisons, the AUC of SUVmax2 was significantly higher than that of SUVmax1 (P = 0.032). The AUC of the RI was higher than those of SUVmax1 and SUVmax2, but the difference was not statistically significant. Dual-phase 18F-FDG PET/CT might be considered when preoperative imaging is indeterminate. A larger-scaled, prospective study is needed to verify these results.
    Journal of Ovarian Research 02/2014; 7(1):15. · 2.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer is among the five most lethal malignancies in the world. Unfortunately, many malignant tumors go undetected by the current primary diagnostic tools. (18)FDG-PET and (18)FDG-PET/CT might be useful to confirm suspected pancreatic cancer. A meta-analysis was performed using all major search engines. Methodological quality of included studies was assessed as well as quality of the PET-protocol. The following pooled estimates served as primary outcome measures: sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy. Thirty-five studies were included. Pooled estimates for (18)FDG-PET were: sensitivity 90%, specificity 76%, PPV 90%, NPV 76% and accuracy 86%. Pooled estimates for (18)FDG-PET/CT were: sensitivity 90%, specificity 76%, PPV 89%, NPV 78% and accuracy 86%. The pooled sensitivity and specificity for (18)FDG-PET to differentiate between pancreatic cancer and chronic pancreatitis were 90% and 84%, respectively. Both (18)FDG-PET and (18)FDG-PET/CT offer no benefit over the current primary diagnostic tools in diagnosing pancreatic cancer. However, the (18)FDG-PET/CT systems are still improving. We should investigate the sensitivity and specificity of these new systems while reevaluating the tradeoff between false positive and false negative results. Yet, (18)FDG-PET/CT may have a role in the staging of pancreatic cancer, in survival prediction, and may add to other diagnostic information, like histology.
    European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 04/2014; · 2.56 Impact Factor
  • Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 11/2013; · 5.64 Impact Factor